Study guide

31.3 Unethical Actions & Human-Subject Research

FACHE Board of Governors Exam in Healthcare Management Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FACHE Credential 1.2 Current Exam Facts 1.3 Eligibility, Application & Recertification

2 Healthcare Systems & Trends

2.1 Healthcare and Medical Terminology 2.2 Healthcare Trends 2.3 Continuum of Care Levels

3 Healthcare Organizations & Services

3.1 Levels of Service from a Business Perspective 3.2 Types of Healthcare Organizations 3.3 Ancillary and Support Services

4 Integration, Clinicians & Staff Perspectives

4.1 Integration, Competition & Partnerships 4.2 Clinician Roles and Qualifying Criteria 4.3 Staff Perspectives & Evidence-Based Management

5 Patient Perspective & Care Delivery

5.1 Patient vs Provider Perspective 5.2 Access, Quality, Cost & Community 5.3 Care Delivery Models and Access Points

6 Digital Health, Population Health & Prevention

6.1 Digital Health 6.2 Population Health Concepts 6.3 Social Determinants & Preventative Medicine

7 Management Planning & Organizational Systems

7.1 Implementation Planning 7.2 Emergency Preparedness & NIMS 7.3 Organizational Systems & Management Functions

8 Leadership, Teams & Change

8.1 Leadership and Communication Styles 8.2 Team-Building Techniques 8.3 Change Management & Organizational Development

9 Collaboration, DEIJ & Networks

9.1 Stakeholder Collaboration 9.2 DEIJ & Resource Allocation 9.3 Network Structures & Collective Bargaining

10 Financial Accounting & Budgeting

10.1 Financial Accounting and Ratios 10.2 Operating Budgets 10.3 Capital Budgeting

11 Reimbursement, Productivity & Controls

11.1 Reimbursement Methodologies 11.2 Productivity Measures 11.3 Financial Controls

12 Revenue, Business Cases & Capital Finance

12.1 Revenue Generation and Payer Mix 12.2 Business Cases & Financial Decision Impacts 12.3 Asset Management & Financing

13 Philanthropy, Supply Chain & Revenue Cycle

13.1 Philanthropy and Foundations 13.2 Supply Chain Management 13.3 Revenue Cycle

14 HR Laws, Recruitment & Staffing

14.1 HR Laws and Regulations 14.2 Recruitment and Retention 14.3 Staffing Methodologies

15 Performance, Engagement & Compensation

15.1 Performance Management Systems 15.2 Motivation, Development & Engagement 15.3 Compensation and Benefits

16 Workplace Safety, Conflict & Labor Relations

16.1 Employee Safety, Security & Health 16.2 Conflict, Grievances & Selection 16.3 Labor Relations & HR Decision Impacts

17 Job Design, Succession & Coaching

17.1 Job Design 17.2 Succession Planning, Mentorship & Coaching

18 Confidentiality, Compliance & Payment Rules

18.1 Confidentiality and Privacy Laws 18.2 Healthcare Compliance Laws 18.3 Medicare, Medicaid & Third-Party Payment Regulations

19 Accreditation, Patient Rights & Ownership Rules

19.1 Accreditation & Inspection Standards 19.2 Patients' Rights Laws 19.3 Nonprofit vs For-Profit Requirements

20 Regulatory Impacts, Labor Law & M&A

20.1 Regulatory Impact on Executive Decisions 20.2 Collective Bargaining Laws 20.3 Legal Implications of Mergers & Acquisitions

21 Benchmarking, Peer Review & Risk

21.1 Benchmarking & Best Practices 21.2 Medical Staff Peer Review 21.3 Risk Management Programs

22 Improvement Methods & Measurement

22.1 PDSA, Lean & Six Sigma 22.2 Clinical Performance Improvement & Pathways 22.3 Quality Measurement & HCAHPS

23 Utilization, Patient Safety & Quality Impacts

23.1 Utilization Review & Case Management 23.2 Patient Safety Tools 23.3 How Quality Impacts Operations

24 Strategic Planning, Business Planning & Contracts

24.1 Strategic Planning Process 24.2 Business Planning for Services 24.3 Business Contracts

25 Socioeconomic Context, Marketing & Media

25.1 Socioeconomic Environment 25.2 Marketing Principles 25.3 Media, Social Media & Community Relations

26 Negotiation & Business Decision Impacts

26.1 Contract Negotiation 26.2 Business Decision Impacts

27 Health IT Operations, Trends & Regulation

27.1 IT in Business Operations 27.2 Technology Trends & Clinical Applications 27.3 HIPAA Security, HITECH & Interoperability

28 Informatics, IT Impacts & Continuity

28.1 Health Informatics for Operational Decisions 28.2 IT Decision Impacts 28.3 Information Systems Continuity

29 IT Acquisition & Analytics

29.1 IT Selection, Acquisition & Maintenance 29.2 Healthcare Analytics & Clinical Informatics

30 ACHE Ethics, Patient Rights & Ethics Committees

30.1 ACHE Code of Ethics 30.2 Patients' Rights & Responsibilities 30.3 Ethics Committees

31 Diversity, Conflicts of Interest & Research Ethics

31.1 Cultural & Spiritual Diversity 31.2 Conflict of Interest 31.3 Unethical Actions & Human-Subject Research

32 Professional Norms, Ethical Culture & Diversity Statement

32.1 Professional Norms & Standards 32.2 Creating an Ethical Culture 32.3 ACHE Statement on Diversity

33 Governance Theory, Structure & Medical Staff

33.1 Governance Theory 33.2 Governance Structure & Operations 33.3 Medical Staff Structure

34 Board Accountability & Public Policy

34.1 Board Role, Accountability & Fiduciary Duty 34.2 Public Policy & Advocacy

31.3 Unethical Actions & Human-Subject Research

Key Takeaways Explain This Topic AI

Unethical actions by executives or organizations produce multi-layered consequences: patient harm, workforce moral injury, legal/regulatory sanctions, accreditation and payment risk, civil and criminal liability, reputational collapse, and personal professional discipline including ACHE ethics processes

Prevention relies on ethical climate, clear policies, non-retaliation reporting, competent compliance and ethics resources, truthful reporting, and leadership modeling—not only post-scandal punishment

Human-subject research ethics rest on respect for persons (informed consent/autonomy), beneficence (risk-benefit), and justice (fair subject selection), operationalized through IRB review, protocol adherence, and protection of vulnerable populations

Historical abuses and modern regulations (including Common Rule frameworks and institutional review) make research ethics an executive responsibility: resource IRBs, prevent coercive enrollment, separate clinical care from research pressures, and manage research COI

FACHE leaders distinguish quality improvement from research when boundaries blur, never trade patient rights for enrollment targets, and treat fabrication, falsification, plagiarism, and cover-ups as severe integrity failures

Last updated: August 2026

Unethical Actions & Human-Subject Research

Quick Answer: Unethical actions in healthcare leadership harm people and trigger cascading organizational and personal consequences—legal, financial, accreditation, reputational, and professional. Human-subject research ethics require voluntary informed consent, favorable risk-benefit balance, fair subject selection, and independent review (typically via an Institutional Review Board / IRB ). FACHE executives must prevent and respond to misconduct and ensure research never treats patients as mere means to data, revenue, or prestige.

This section maps ACHE knowledge on consequences of unethical actions (E6) and ethical implications of human-subject research (E7). Both themes ask whether leaders protect dignity when pressure rewards silence, speed, or enrollment numbers.

Consequences of Unethical Actions

Unethical conduct ranges from individual integrity failures (lying, self-dealing, harassment, covering up harm) to organizational patterns (fraudulent billing culture, discriminatory access, retaliatory management, misleading advertising). Consequences are multi-level:

Level Illustrative consequences

Patients & community Physical/psychological harm, lost trust, inequitable access, delayed care after safety events

Workforce Moral distress, turnover, silence about safety, normalized deviance

Organization Civil settlements, False Claims Act exposure, corporate integrity agreements, exclusion from federal programs, loss of tax-exempt status factors, bond/rating damage, volume loss

Regulators & accreditors CMS sanctions, state license actions, accreditation jeopardy, mandated monitors

Individuals Termination, license/board actions, criminal charges, civil liability, ACHE ethics grievances and membership consequences

Mission & strategy Leadership distraction, capital freeze, partnership collapse, community opposition

Exam insight: “We saved money” does not offset ethical failure when harm and deception were the methods. ACHE frames executives as models; personal misconduct and organizational cover-ups both count.

Prevention and Response Systems

Ethical organizations reduce misconduct probability and damage severity through:

  • Clear standards — code of conduct, COI, privacy, research integrity, anti-retaliation
  • Training and decision support — scenario-based learning for leaders and high-risk roles
  • Safe reporting — hotlines, ombuds, open-door practice, protection from retaliation
  • Investigation capacity — fair, prompt, competent fact-finding with board oversight for serious matters

Just culture principles — distinguish human error, at-risk behavior, and reckless conduct; avoid pure blame that drives underground reporting while still holding reckless and intentional misconduct accountable

Transparent remediation — disclosure to patients when appropriate, corrective action, system redesign, truthful external reporting when required

Leadership accountability — executives who pressure staff to falsify quality data or hide adverse events must face consequences, not only frontline staff

Cover-ups often exceed the original wrong in damage. FACHE scenarios frequently reward early honesty, patient protection, and process integrity over image management.

Foundations of Human-Subject Research Ethics

Modern research ethics grew from recognition of exploitation (e.g., historical atrocities and domestic research abuses) and from principles articulated in frameworks such as the Belmont Report themes still taught to leaders:

  • Respect for persons — autonomy; informed consent; extra protections for those with diminished autonomy
  • Beneficence — do not harm; maximize benefits and minimize risks; continuous risk monitoring

Justice — fair distribution of research burdens and benefits; avoid exploiting vulnerable populations for others’ gain

These principles are operationalized through protocol design, consent processes, data safety monitoring when appropriate, and independent ethical review .

IRB / Ethics Review and Executive Duties

An Institutional Review Board (IRB) (or equivalent ethics review body) reviews research involving human subjects to protect participants’ rights and welfare. Executive responsibilities include:

  • Duty Why it matters
  • Resource the IRB Adequate expertise, staffing, and independence
  • Require review before research begins No “start now, approve later” enrollment
  • Protect voluntary participation No coercion via employment, immigration fear, or care access threats
  • Separate clinical care from research pressure Treat first; enroll only with valid consent
  • Manage research COI Investigator and institutional financial interests disclosed and managed
  • Support compliance Protocol deviations, adverse event reporting, suspension when needed
  • Educate investigators Good clinical practice and research integrity

Clarify QI vs. research When activities generate generalizable knowledge, ethics review pathways must be correct

Leaders should not treat IRB approval as a rubber stamp for scientifically weak or exploitative studies. Nor should they pressure IRBs to approve high-revenue trials that fail risk-benefit or consent standards.

Informed Consent in Research

Research consent differs from clinical consent in purpose: participants accept uncertainty and contribute to knowledge that may not benefit them personally. Ethical consent includes understanding of purpose, procedures, risks, benefits, alternatives (including standard care without research), confidentiality limits, voluntary nature, and right to withdraw without penalty to clinical care. Special attention applies to:

  • Emergency research and waiver/exception pathways only under strict regulatory criteria
  • Children (parental permission and assent as applicable)
  • Decisionally impaired adults (surrogate rules and additional safeguards)
  • Economically or educationally disadvantaged persons (avoid undue inducement)
  • Employees and students (avoid hierarchical coercion)
  • Non-English speakers (translated consent and interpreters)

Paying participants may be ethical when not coercive; excessive payments that cloud risk judgment raise red flags. Care access must never be conditioned on research enrollment.

Unethical Research Practices and Integrity Failures

Executives should recognize and stop:

  • Fabrication, falsification, plagiarism in data or publications
  • Enrolling ineligible subjects to meet targets
  • Withholding information about risks or commercial interests
  • Using residual clinical specimens or data for research without required approvals/consents
  • Ghostwriting that conceals industry control of scientific messaging
  • Retaliating against research staff who report protocol violations

Consequences mirror general unethical action consequences—plus research debarment, loss of federal funding eligibility, journal retractions, and destroyed scientific credibility.

Linking Unethical Organizational Acts and Research Risk

A culture that tolerates billing fraud, COI secrecy, or safety cover-ups rarely protects research subjects well. Conversely, strong ethics infrastructure (committee, compliance, just culture, COI management) reduces both operational misconduct and research exploitation. ACHE’s expectation that executives ensure ethics resources for clinical, organizational, and research issues is a single leadership system, not three unrelated silos.

  • Common Exam Traps
  • CEO orders IRB to “fast-track” a lucrative trial without complete review
  • Conditioning free care or opioid prescriptions on study enrollment
  • Treating quality-improvement projects that are actually research as exempt from review without analysis
  • Punishing a nurse who reports falsified research vital signs

Assuming only academic medical centers need research ethics capacity (community sites in multi-center trials still need protections)

  • Focusing only on external PR after misconduct rather than patient remediation and system fix
  • Executive Decision Lens

When facing alleged unethical action: Who is at risk right now, and how do we protect them? What facts must be gathered fairly? What must be disclosed to patients, boards, or authorities? How do we prevent retaliation and recurrence? When facing research proposals: Is consent truly voluntary and understandable? Are risks minimized and justified? Is subject selection fair? Is the IRB independent and resourced? Are investigator conflicts managed? Unethical shortcuts buy temporary metrics and sell long-term trust. Human-subject research, done right, advances knowledge while treating every participant as a person with rights—never as raw material for prestige, publication, or revenue.